Targeted Therapy of Acute Myeloid Leukemia

Introduction/Perspective.- Genetics and Classification of Acute Myeloid Leukemia.- Proteomics of AML to guide Selection of Therapy.- Roles of Apoptosis Regulating Bcl-2-Family Genes in AML.- Bcl-2 family: Translational aspects.- IAP Family and Proteins as Therapeutic Targets for Acute Myeloid Leukemia.- TP53 Mutations in Acute Myeloid Leukemia.- Targeting p53 Tumor Suppressor for AML Therapy.- AML-Selective Apoptosis Induction by rationally designed Death Ligand Fusion Protein.- PIM Kinases in AML.- Development of Midostaurin as a Tyrosine Kinase Inhabitor.- FLT3 in AML.- FLT3-ITD. Clinical (Sorafenib/AC220).- Nucleophosmin (NPM1).- Raf/MEK Pathway.- The Role of Translational Medicine in Optimization of Therapies targeting the RAS-MAP Kinase Pathway.- Clinical Use of Farnesyltransferase Inhititors.- The P13K-AKT-mTOR signaling Network in AML.- Targeting the P13 Kinase-mTOR Signaling Pathway in AML.- Aurora kinases.- The Clinical Development of Aurora Kinase Inhibitors in Acute Myeloid Leukemia.- AML-Deacetylases.- Methylation in AML-Clinical Applications.- Topic: RARa/RXR Part: Basic.- Arsenic Trioxide in Untreated APL.- Targeting PML-RAR with Retinoids.- NR4A Orphan Receptors as Drug Targets.- Antibody-based Therapeutics Targeting CD33, CD45, and CD66.- New Heterogeneity of the Leukemic Stem Cells.- Targeting Leukemia Stem Cells.- Regulation of Hematopoiesis by CXCL12/CXCR4 Signaling.- CXC4/CXCL12 as a Therapeutic Target.- VLA-4: A Cell's Consequential Encounter.- VLA-4 Function and Prognosis in Acute Myeloid Leukemia.- VLA4 in Acute Lymphoblastic Leukemia.- The Leukemic Bone Marrow Microenvironment: Targeting Hypoxia with Hypoxia Activated Pro-Drugs.- Topic: miRs as Therapeutic Targets.- Clinical Implications of MicroRNAs in AML.- Inhibition of Glycolysis as a Therapeutic Strategy in Acute Myeloid Leukemias.- Molecular and Biochemical Basis for the Reprogramming of Intermediary Metabolism in Leukemia Cells.- NK Cell Immunotherapy for AML.- Allogeneicand Autologous